UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, ~~2022~~2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37467

Astria Therapeutics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware		26-3687168
(State or Other Jurisdiction of Incorporation or Organization)		(IRS Employer Identification No.)

~~100 High~~75 State Street ~~Floor 28~~Suite 1400
Boston, Massachusetts		~~02110~~02109
(Address of Principal Executive Offices)		(Zip Code)

(617) 349-1971

(Registrant’s Telephone Number, Including Area Code)

Securities Registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value per share		ATXS		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ⌧☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ⌧☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of April ~~29, 2022,~~28, 2023, there were ~~13,016,955~~28,025,844 shares of the registrant’s common stock, par value $0.001 per share, outstanding.

Table of Contents

TABLE OF CONTENTS


		Page
PART I. FINANCIAL INFORMATION		23
Item 1.	Financial Statements (unaudited)	23
	Condensed Consolidated Balance Sheets as of March 31, ~~2022~~2023 and December 31, ~~2021~~2022	23
	Condensed Consolidated Statements of Operations for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022	34
	Condensed Consolidated Statements of Comprehensive Loss for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022	45
	Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022	56
	Condensed Consolidated Statements of Cash Flows for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022	68
	Notes to Condensed Consolidated Financial Statements	79
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	1617
Item 4.	Controls and Procedures	2524

PART II. OTHER INFORMATION		2625
Item 1A.	Risk Factors	2625
Item 6.	Exhibits	2625

SIGNATURES		2726

Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Quarterly Report on Form 10-Q contains forward-looking statements, , which reflect our current views with respect to, among other things, our operations and financial performance, strategy, future financial condition and clinical development programs. Such forward-looking statements are subject to various risks and uncertainties. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, clinical development programs, regulatory filings and expected market growth are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements include, among other things, statements about:

●

our expectations regarding the potential significance of the preliminary results from the Phase 1a STAR-0215 clinical trial and the anticipated nature and timing of receipt of the data from additional cohorts in such trial;

●

our ~~planned filing of an investigational new drug application for STAR-0215, and~~expectations regarding the timing, ~~plans,~~nature, goals and results of our ~~planned Phase 1a and~~ Phase 1b/2 clinical ~~trials~~trial of STAR-0215 ~~including~~and that favorable results from such ~~trials~~trial could ~~establish proof of concept for the differentiation~~allow us to move directly into a pivotal trial of STAR-0215 as a potential treatment for hereditary angioedema, ~~(“HAE”);~~or HAE;

●

our expectations about the design of a pivotal clinical trial for STAR-0215 as a potential treatment for HAE, assuming positive data from the Phase 1b/2 trial;

●

our expectations about the unmet medical need for HAE, the potential differentiating attributes of STAR-0215 as a potential treatment for HAE, along with the potential market impact of such differentiation, the potential of STAR-0215 to be a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE, and our vision for STAR-0215 to become the ~~most patient friendly~~first-choice preventative treatment for HAE ~~and~~ with administration every three or six months with the goal of normalizing the lives of people living with HAE;

●

the nature and anticipated growth of the global HAE market and HAE therapies;

●

our plans to improve the formulation of STAR-0215 and corresponding work to develop a drug-device combination for STAR-0215 for potential use in late-stage clinical trials and commercially, if approved;

●

our expectations that we have ~~identified a stable~~scaled the manufacturing process for STAR-0215 cell line ~~for STAR-0215 and the ability of such cell line~~in a manner to generate sufficient material ~~of suitable and appropriate quality~~ for our planned STAR-0215 ~~preclinical~~nonclinical and clinical ~~studies in a timely manner;~~studies;

●

our expectations regarding our ability to expand our pipeline;

●

the potential benefits of any future acquisition, in-license, collaboration or preclinical development activities;

●

our manufacturing plans, capabilities and strategy;

●

our intellectual property position and strategy;

●

our estimates regarding ~~our cash runway,~~ expenses, future ~~revenues,~~revenue, capital requirements and needs for additional financing, including additional financing to fund our long-term operations;

●

developments relating to our competitors and our industry; and

●

the impact of government laws and regulations.

Table of Contents

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021,~~2022, particularly in the sections entitled “Summary of the Material Risks Associated with Our Business” and “Risk Factors”, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.

Table of Contents

PART I- FINANCIAL INFORMATION

Item 1. Financial Statements

Astria Therapeutics, Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share and per share data)

(Unaudited)


	March 31,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Assets
Current assets:
Cash and cash equivalents	$	46,687	$	86,508	$	202,301	$	20,525
Short-term investments		66,129		39,000		11,027		205,912
Prepaid expenses and other current assets		1,405		1,567		2,117		1,253
Total current assets		114,221		127,075		215,445		227,690
Right-of-use asset		228		394		806		948
Other assets		204		45		1,989		1,995
Total assets	$	114,653	$	127,514	$	218,240	$	230,633
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	931	$	1,557	$	930	$	788
Accrued expenses		3,852		3,281		5,156		7,690
Current portion of operating lease liabilities		184		365		587		582
Total current liabilities		4,967		5,203		6,673		9,060
Long term portion of operating lease liabilities						207		357
Total liabilities		4,967		5,203		6,880		9,417
Commitments (Note 7)
Commitments (Note 6)
Stockholders’ equity:
Preferred stock, $0.001 par value per share, 4,908,620 shares authorized and 0 shares issued and outstanding		—		—
Series X redeemable convertible preferred stock, $0.001 par value per share, 91,380 shares authorized; 31,455 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively		96,398		96,398
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 13,016,955 shares issued and outstanding at March 31, 2021 and December 31, 2021, respectively		13		13
Preferred stock, $0.001 par value per share, 4,908,620 shares authorized and no shares issued and outstanding						—		—
Series X redeemable convertible preferred stock, $0.001 par value per share, 91,380 shares authorized; 31,107 and 31,455 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively						95,324		96,398
Common stock, $0.001 par value per share, 150,000,000 shares authorized; 27,986,718 and 27,501,340 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively						28		28
Additional paid-in capital		484,460		481,709		634,843		632,512
Accumulated other comprehensive loss		(53)		—		(4)		(79)
Accumulated deficit		(471,132)		(455,809)		(518,831)		(507,643)
Total stockholders’ equity		109,686		122,311		211,360		221,216
Total liabilities and stockholders’ equity	$	114,653	$	127,514	$	218,240	$	230,633

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Operations

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended March 31,

2022

2021
Operating expenses:

Research and development

$
10,358

$
2,593
General and administrative

5,020

2,880
Acquired in-process research and development

—

164,612
Total operating expenses

15,378

170,085
Loss from operations

(15,378)

(170,085)
Other income (expense):

Interest and investment income

56

14
Other expense, net

(1)

(13)
Total other income, net

55

1
Net loss

(15,323)

(170,084)
Net loss per share - basic and diluted

$
(1.18)

$
(45.60)
Weighted-average common shares outstanding used in net loss per share - basic and diluted

13,016,955

3,730,029


	Three Months Ended March 31,
	2023		2022
Operating expenses:
Research and development	$	8,033	$	10,358
General and administrative		5,460		5,020
Total operating expenses		13,493		15,378
Loss from operations		(13,493)		(15,378)
Other income (expense):
Interest and investment income		2,321		56
Other expense, net		(16)		(1)
Total other income, net		2,305		55
Net loss		(11,188)		(15,323)
Net loss per share attributable to common shareholders - basic and diluted	$	(0.40)	$	(1.18)
Weighted-average common shares outstanding used in net loss per share - basic and diluted		27,944,458		13,016,955

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Comprehensive Loss

(In thousands)

(Unaudited)


	Three Months Ended March 31,				Three Months Ended March 31,
	2022		2021		2023		2022
Net loss	$	(15,323)	$	(170,084)	$	(11,188)	$	(15,323)
Other comprehensive income:
Unrealized loss on short-term investments, net of tax of $0		(53)		—
Total other comprehensive loss		(53)		—
Other comprehensive gain (loss):
Unrealized gain (loss) on short-term investments, net of tax of $0						75		(53)
Total other comprehensive gain (loss):						75		(53)
Comprehensive loss	$	(15,376)	$	(170,084)	$	(11,113)	$	(15,376)

The accompanying notes are an integral part of these condensed consolidated financial ~~statements~~statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except shares)

(Unaudited)


	Series X	Series X
	redeemable	redeemable										Accumulated		Total
	convertible	convertible						Additional				other		stockholders’
	preferred stock,	preferred stock,		Common stock,		Common stock,		paid-in		Accumulated		comprehensive		equity
	shares	value		shares		par value		capital		deficit		loss		(deficit)
Balance at December 31, 2022	31,455	$	96,398		27,501,340	$	28	$	632,512	$	(507,643)	$	(79)	$	221,216
Issuance of common stock upon the conversion of preferred stock	(348)		(1,074)		57,910		—		1,074		—		—		—
Issuance of common stock upon exericse of options and warrants	—		—		427,468		—		37		—		—		37
Stock-based compensation expense	—		—		—		—		1,220		—		—		1,220
Unealized gain on short-term investments	—		—		—		—		—		—		75		75
Net loss	—		—		—		—		—		(11,188)		—		(11,188)
Balance at March 31, 2023	31,107	$	95,324		27,986,718	$	28	$	634,843	$	(518,831)	$	(4)	$	211,360

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Series X

Series X

Series X

Series X

redeemable

redeemable

redeemable

redeemable

Accumulated

Total

convertible

convertible

convertible

convertible

Common

Common

Additional

other

stockholders’

preferred

preferred

preferred

preferred

stock,

stock, par

paid-in

Accumulated

comprehensive

equity


stock, shares

stock, value


stock, shares

stock, value

shares

value

capital

deficit

loss

(deficit)
Balance at December 31, 2020

0

$
0

—

$
—

3,347,386

$
4

$
301,562

$
(260,897)

$
—

$
40,669
Issuance of preferred stock in a private offering of public equity, net of issuance costs

35,573

84,696

—

—

—

—

19,565

—

—

19,565
Issuance of preferred stock and common stock upon acquisition of Quellis

50,504

156,185

—

—

555,444

—

8,098

—

—

8,098
Expense related to warrants inherited in acquisiton of Quellis

—

—

—

—

—

—

241

—

—

241
Stock-based compensation expense

—

—

—

—

—

—

366

—

—

366
Net loss

—

—

—

—

—

—

—

(170,084)

—

(170,084)
Balance at March 31, 2021

86,077

$
240,881

—

$
—

3,902,830

$
4

$
329,832

$
(430,981)

$
—

$
(101,145)

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity

(In thousands, except shares)

(Unaudited)



	Series X	Series X		Series X	Series X													Series X	Series X
	redeemable	redeemable		redeemable	redeemable									Accumulated		Total		redeemable	redeemable										Accumulated		Total
	convertible	convertible		convertible	convertible		Common	Common		Additional				other		stockholders’		convertible	convertible						Additional				other		stockholders’
	preferred	preferred		preferred	preferred		stock,	stock, par		paid-in		Accumulated		comprehensive		equity		preferred stock,	preferred stock,		Common stock,		Common stock,		paid-in		Accumulated		comprehensive		equity
	stock, shares	stock, value		stock, shares	stock, value		shares	value		capital		deficit		loss		(deficit)		shares	value		shares		par value		capital		deficit		loss		(deficit)
Balance at December 31, 2021	—	$	—	31,455	$	96,398	13,016,955	$	13	$	481,709	$	(455,809)	$	0	$	122,311	31,455	$	96,398		13,016,955	$	13	$	481,709	$	(455,809)	$	—	$	122,311
Expense related to warrants inherited in acquisiton of Quellis	—		—	—		—	—		—		1,542		—		—		1,542	—		—		—		—		1,542		—		—		1,542
Stock-based compensation expense	—		—	—		—	—		—		1,209		—		—		1,209	—		—		—		—		1,209		—		—		1,209
Unrealized loss on short-term investments	—		—	—		—	—		—		—		—		(53)		(53)	—		—		—		—		—		—		(53)		(53)
Net loss	—		—	—		—	—		—		—		(15,323)		—		(15,323)	—		—		—		—		—		(15,323)		—		(15,323)
Balance at March 31, 2022	—	$	—	31,455	$	96,398	13,016,955	$	13	$	484,460	$	(471,132)	$	(53)	$	109,686	31,455	$	96,398		13,016,955	$	13	$	484,460	$	(471,132)	$	(53)	$	109,686

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

Three Months Ended March 31,

2022

2021
Operating activities

Net loss

$
(15,323)

$
(170,084)
Reconciliation of net loss to net cash used in operating activities:

Non-cash portion of acquired in-process research and development

—

164,612
Stock-based compensation expense

1,209

366
Expense for warrants inherited in acquisiton of Quellis

1,542

55
Other non-cash items

(79)

4
Changes in assets and liabilities:

Prepaid expenses and other assets

163

767
Right-of-use asset- operating

(15)

(73)
Accounts payable

(627)

(1,712)
Accrued expenses

571

(2,651)
Net cash used in operating activities

(12,559)

(8,716)
Investing activities

Purchases of short-term investments

(81,702)

—
Sales and maturities of short-term investments

54,603

20,000
Cash acquired in acquisition of Quellis

—

6,466
Purchases of property and equipment

—

(21)
Net cash (used in) provided by investing activities

(27,099)

26,445
Financing activities

Proceeds from private offering of public equity, net of issuance costs

—

104,261
Net cash provided by financing activities

—

104,261
Net (decrease) increase in cash, cash equivalents and restricted cash

(39,658)

121,990
Cash, cash equivalents and restricted cash, beginning of period

86,629

25,051
Cash, cash equivalents and restricted cash, end of period

$
46,971

$
147,041


	Three Months Ended March 31,
	2023		2022
Operating activities
Net loss	$	(11,188)	$	(15,323)
Reconciliation of net loss to net cash used in operating activities:
Stock-based compensation expense		1,220		1,209
Net gain on warrants inherited in acquisition of Quellis		—		1,542
Right-of-use asset - operating lease		142		—
Other non-cash items		(26)		(79)
Changes in assets and liabilities:
Prepaid expenses and other assets		(864)		163
Lease liability - operating lease		(145)		(15)
Accounts payable		140		(627)
Accrued expenses		(2,532)		571
Net cash used in operating activities		(13,253)		(12,559)
Investing activities
Purchases of short-term investments		(95,923)		(81,702)
Sales and maturities of short-term investments		290,920		54,603
Purchases of property and equipment		(5)		—
Net cash provided by (used in) investing activities		194,992		(27,099)
Financing activities
Proceeds from exercise of stock options		37		—
Net cash provided by financing activities		37		—
Net increase (decrease) in cash, cash equivalents and restricted cash		181,776		(39,658)
Cash, cash equivalents and restricted cash, beginning of period		20,688		86,629
Cash, cash equivalents and restricted cash, end of period	$	202,464	$	46,971
Supplemental disclosure of non-cash transactions:
Conversion of Series X Preferred Stock into common stock	$	1,074	$	—

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

Astria Therapeutics, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.	1.Organization and Operations

The Company

Astria Therapeutics, Inc. (the “Company”), formerly known as Catabasis Pharmaceuticals, Inc., is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Its mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. On October 26, 2020, the Company announced that the Phase 3 PolarisDMD trial of the Company’s previous lead product candidate, edasalonexent, for the treatment of Duchenne Muscular Dystrophy ~~(“DMD”)~~ did not meet its primary and secondary endpoints. Based on these results, the Company announced that it was stopping activities related to the development of edasalonexent, including the Company’s ongoing open-label extension trial. On January 28, 2021, the Company acquired Quellis Biosciences, Inc. (“Quellis”). The Company’s lead product candidate, which was acquired in the Quellis acquisition, is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein in ~~preclinical~~clinical development for the treatment of hereditary angioedema (“HAE”), a rare, debilitating and potentially life-threatening disease. The Company was incorporated in the State of Delaware on June 26, 2008.

~~Reverse Stock Split~~

~~On August 19, 2021, the Company effected a reverse stock split of its outstanding shares of common stock at a ratio of~~ ~~one~~-for-six (1:6) pursuant to a Certificate of Amendment to its Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware. Pursuant to the reverse stock split, every six shares of the Company’s issued and outstanding shares of common stock were automatically combined into one issued and outstanding share of common stock, without any change in the par value per share of the common stock. Amounts of common stock resulting from the reverse stock split were rounded down to the nearest whole share and any resulting fractional shares were cancelled for cash. The number of authorized shares of the Company’s common stock remained unchanged. The reverse stock split affected all issued and outstanding shares of the Company’s common stock, and the respective numbers of shares of common stock underlying the Company’s outstanding Series X Preferred Stock (as defined below), outstanding stock options, outstanding warrants and the Company’s equity incentive plans were proportionately adjusted. All share and per share amounts of the common stock included in the accompanying unaudited condensed consolidated financial statements have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital.

~~Agreement and Plan of Merger~~

On January 28, 2021, the Company acquired Quellis (the “Quellis Acquisition”). Under the terms of that certain agreement and plan of merger, dated January 28, 2021 (the “Merger Agreement”), the Company issued to the stockholders of Quellis 555,444 shares of the Company’s common stock, par value $0.001 per share, and 50,504 shares of newly designated Series X redeemable convertible preferred stock (“Series X Preferred Stock”) (as described below). The Series X Preferred Stock had a conversion value on the closing date of $122.7 million. In addition, the Company assumed options granted under the Quellis 2019 Stock Incentive Plan, which became options to purchase 55,414 shares of the Company’s common stock, a warrant to purchase 2,805 shares of Series X Preferred Stock at an exercise price of $341.70 per share, and a warrant to purchase 30,856 shares of the Company’s common stock at an exercise price of $2.10 per share, which warrants are exercisable until December 14, 2030. Upon stockholder approval of the Conversion Proposal (as defined below) on June 2, 2021, the warrant to purchase Series X Preferred Stock was converted into the right to purchase 467,500 shares of the Company’s common stock at a per share exercise price of $2.10 per share.

~~Stock Purchase Agreement and Series X Preferred Stock~~

Concurrent with the Quellis Acquisition, the Company entered into a Stock Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors. Pursuant to the Purchase Agreement, the Company sold an aggregate of 35,573 shares of Series X Preferred Stock for gross proceeds of approximately $110.0 million, and net proceeds of $104.3 million (the “February 2021 Financing”). Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock. In accounting for the Purchase Agreement, the Company recorded a beneficial conversion feature of $19.6 million and issuance costs of $5.7 million. The combined

~~Table of Contents~~

~~total was treated as a discount to the value of Series X Preferred Stock, see Note 2 , “~~~~Summary of Significant Accounting Policies~~~~” for further discussion.~~

~~As a result of the Quellis Acquisition and the February 2021 Financing, the Company issued the following Series X Preferred Stock and assumed the following warrant:~~

Series X

Common Stock

Preferred

Issuable Upon

Stock at

Conversion at

Transaction

Transaction

Date

Date
Shares issued in merger

50,504

8,417,502
Shares issued in February 2021 Financing

35,573

5,928,952
Warrant assumed in merger

2,805

467,500
Total

88,882

14,813,954

At its Annual Meeting of Stockholders on June 2, 2021, the Company’s stockholders approved the conversion of the Company’s Series X Preferred Stock into shares of the Company’s common stock in accordance with Nasdaq Listing Rule 5635(a) (the “Conversion Proposal”). Following stockholder approval of the Conversion Proposal, each share of Series X Preferred Stock then outstanding automatically converted into 166.67 shares of the Company’s common stock, subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (as of March 31, 2022, these percentages are set at 4.99% to 9.99% and can be adjusted by the holder to a number between 4.99% and 19.99)% of the total number of shares of the Company’s common stock issued and outstanding immediately after giving effect to such conversion. As of March 31, 2022, 54,622 shares of Series X Preferred Stock have been converted into 9,103,664 shares of common stock and 31,455 shares of Series X Preferred Stock remained outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock. At March 31, 2022, the number of shares of common stock issuable upon conversion of the remaining outstanding shares of Series X Preferred Stock is 5,242,501. Outstanding shares of Series X Preferred Stock are subject to conversion at the option of the holder.

Holders of Series X Preferred Stock are entitled to receive dividends, subject to certain beneficial ownership limitations, on shares of Series X Preferred Stock equal, on an as-if-converted-to-common-stock basis, and in the same form as dividends actually paid on shares of the Company’s common stock. Except as otherwise required by law, the Series X Preferred Stock does not have voting rights. However, as long as any shares of Series X Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series X Preferred Stock, (i) alter or change adversely the powers, preferences or rights given to the Series X Preferred Stock or alter or amend the Certificate of Designation that authorized the Series X Preferred Stock, amend or repeal any provision of, or add any provision to, the Company’s Restated Certificate of Incorporation or bylaws, or file any articles of amendment, certificate of designations, preferences, limitations and relative rights of any series of preferred stock, if such action would adversely alter or change the preferences, rights, privileges or powers of, or restrictions provided for the benefit of the Series X Preferred Stock, (ii) issue further shares of Series X Preferred Stock or increase or decrease (other than by conversion) the number of authorized shares of Series X Preferred Stock, or (iii) enter into any agreement with respect to any of the foregoing.

Liquidity

The Company had entered into various sales agreements with Cowen and Company LLC (“Cowen”), pursuant to which the Company could issue and sell shares of common stock under at-the-market offering programs. On May 20, 2021, the Company terminated its sales agreement with Cowen. On June 30, 2021, the Company entered into an Open Market Sale Agreement^SM with Jefferies LLC ~~(“Jefferies”~~("Jefferies"), pursuant to which the Company can issue and sell shares of common stock of up to $25.0 million under ~~at-the-market offering programs (collectively, with the Cowen~~an at-the-market offering program ~~the “ATM Programs”~~(the “Jefferies ATM Program”). The Company pays ~~the~~Jefferies sales agent commissions of 3% of the gross proceeds from any common stock sold through the Jefferies ATM ~~Programs.~~Program. On September 15, 2022, the Jefferies ATM Program was modified to increase the amount of the Company’s common stock that may be offered thereunder to an aggregate offering price of up to $50.0 million, with $30.5 million of such amount then being available for future issuance. In November 2022, the Jefferies ATM Program was once again modified to increase the amount of the Company’s common stock that may be offered thereunder to an aggregate offering price of up to $88.1 million, with $50.0 million of such amount then being available for future issuance. As of March 31, ~~2022, the Company has not sold any shares~~2023, $50.0 million of common stock ~~pursuant to~~remains available for sale under the Jefferies ~~agreement .~~ATM Program. There was ~~also~~ no activity from the Jefferies ATM ~~Programs~~Program during the three months ended March 31, ~~2021.~~2023 or 2022.

As of March 31, 2023, the Company had an accumulated deficit of $518.8 million and had available cash, cash equivalents and short-term investments $213.3 million. The Company ~~is subject~~estimates its existing cash, cash equivalents, and short-term investments are sufficient to ~~a number~~sustain operations for at least twelve months from the issuance of risks similar to other life science companies, including, but not limited to, successful discovery and development of its drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company’s products.these unaudited condensed consolidated financial statements. The

~~Table of Contents~~

Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. ~~The Company anticipates that it will continue to incur significant operating losses and negative cash flows for the next several years as it continues to develop its product candidates.~~

As of March 31, 2022, the Company had an accumulated deficit of $471.1 million and had available cash, cash equivalents and short-term investments of $112.8 million. The Company has determined that its existing cash, cash equivalents and short-term investments will be sufficient to meet its projected operating expenses and capital expenditure requirements for at least twelve months from the date of issuance of these unaudited condensed consolidated financial statements. The Company has not generated any product revenues and has financed its operations primarily through public offerings and private placements of its equity securities. There can be no assurance that the Company will be able to obtain additional debt, equity or other financing or generate product revenues or revenues from collaborative partners, on terms acceptable to the Company, on a timely basis or at all. Management’s conclusion with respect to its ability to fund its operations is based on estimates that are subject to risks and uncertainties that may prove to be incorrect. If actual results differ from management’s estimates,The failure of the Company ~~may be required~~ to ~~seek additional funding or curtail planned activities to reduce operating expenses, which may~~obtain sufficient funds on acceptable terms when needed could have ana material adverse ~~impact~~effect on the Company’s ~~ability~~business, results of operations, and financial condition.

The Company is subject to ~~achieve~~a number of risks similar to other life science companies, including, but not limited to, successful discovery and development of its ~~business objectives.~~drug candidates, raising additional capital, development by its competitors of new technological innovations, protection of proprietary technology and regulatory approval and market acceptance of the Company’s products. The Company has been primarily involved with research and development activities and has incurred operating losses and negative cash flows from operations since its inception. The Company anticipates that it will continue to incur significant operating losses for the next several years as it continues to develop its product candidates.

Table of Contents

2.	Summary of Significant Accounting Policies

Basis of Presentation and Principles of Consolidation

The accompanying financial statements and the related disclosures are unaudited and have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”). Additionally, certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted from this report. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the financial statements as of and for the year ended December 31, ~~2021~~2022 and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, ~~2021~~2022 (the ~~“2021~~“2022 Annual Report on Form 10-K”).

The unaudited condensed consolidated financial statements have been prepared on the same basis as the audited financial statements. In the opinion of the Company’s management, the accompanying unaudited condensed consolidated financial statements contain all adjustments, including those adjustments that are of a normal and recurring nature, which are necessary to fairly present the Company’s results for the interim periods presented. The results for the three months ended March 31, ~~2022~~2023 are not necessarily indicative of the results for the year ending December 31, ~~2022~~2023 or for any future period.

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries, Astria Securities Corporation and Quellis Biosciences, LLC, successor in interest to Quellis. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of the Company’s unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results could differ from such estimates.

The Company utilizes certain estimates to record expenses relating to research and development contracts. These contract estimates, which are primarily related to the length of service of each contract and the amount of service provided as of each measurement date, are determined by the Company based on input from internal project management, as well as from the Company’s service providers.

Net Loss Per Share

Basic net loss per share is calculated by dividing net loss attributable by the weighted average shares outstanding during the period, without consideration for common stock equivalents. Diluted net loss per share is calculated by adjusting weighted average shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using the treasury-stock method. For purposes of the Company’s dilutive net loss per share calculation, preferred stock, stock options and warrants to purchase common stock and preferred stock were considered to be common stock equivalents but were excluded from the calculation of diluted net loss per share as their effect would be anti-dilutive; therefore, basic and diluted net loss per share were the same for all periods presented.

~~Table of Contents~~

The following common stock equivalents, including Series X Preferred Stock shown as common stock equivalents, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect:


	Three Months Ended March 31,		Three Months Ended March 31,
	2022	2021	2023	2022
Series X Preferred Stock	5,242,501	14,346,167	5,184,591	5,242,501
Stock options	1,962,650	271,887	2,562,234	1,962,650
Common stock warrants	1,530,176	1,063,148	1,031,820	1,530,176
Preferred stock warrants	—	467,500
	8,735,327	16,148,702	8,778,645	8,735,327

Cash, Cash Equivalents and Restricted Cash

Cash equivalents are short-term, highly liquid investments that are readily convertible into cash, with original maturities of three months or less. Cash equivalents are mainly comprised of money market accounts invested in U.S. Treasury securities, corporate debt securities, commercial paper and reverse repurchase agreements.

Table of Contents

Restricted cash is comprised of deposits with a financial institution used to collateralize letters of credit related to the Company’s lease arrangements. Restricted cash is presented as a component of other long-term assets at March 31, 2023 and prepaid expenses and other current assets and other long-term assets at March 31, ~~2022 and other long-term assets at March 31, 2021.~~2022.

The reconciliation of cash, cash equivalents and restricted cash reported within the applicable condensed consolidated balance sheet that sum to the total of the same such amount shown in the condensed consolidated statement of cash flows is as follows (in thousands):


	March 31,				March 31,
	2022		2021		2023		2022
Cash and cash equivalents	$	46,687	$	146,920	$	202,301	$	46,687
Restricted cash		284		121		163		284
Total	$	46,971	$	147,041	$	202,464	$	46,971

~~Acquired In-Process Research and Development~~

The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. Goodwill is not recognized in asset acquisitions. In an asset acquisition, the cost allocated to acquire in-process research and development (“IPR&D”) with no alternative future use is charged to expense at the acquisition date. Refer to Note 3, “~~Acquisition of Quellis~~~~” for a more detailed description of the accounting policy utilized for the recent asset acquisition.~~

Preferred Stock Discount

~~As discussed above, in~~In February 2021, the Company issued Series X Preferred Stock in a private placement transaction. It was determined that this transaction resulted in recognition of a beneficial conversion feature, which was valued based on the difference between the price of the shares of common stock on the date of commitment and the conversion price on the closing date, resulting in a total value of $19.6 million. Additionally, the Company incurred total issuance costs of $5.7 million related to the private placement. Both of these features were recorded as a discount on Series X Preferred Stock recognized at the close of the transaction. These features are analogous to preferred dividends and are recorded as a non-cash return to holders of Series X Preferred Stock through additional paid in capital. The discount related to the beneficial conversion feature iswas recognized through the earliest possible date of conversion, which occurred ~~upon stockholder approval of the conversion~~ in June 2021. The issuance costs are recognized as a dividend at the time of conversion to common shares. As of March 31, 2022, $24.4 million of the above amounts were accounted for as a non-cash dividend related to shares of Series X Preferred Stock, and $0.9 million remained to be recognized upon future conversion.

Recent Accounting Pronouncements - ~~Not Yet~~ Adopted

From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date.

~~Table of Contents~~

In June 2016, the FASB issued Accounting Standards Update ~~(“ASU”)~~ 2016-13, Financial Instruments-Credit Losses (Topic 326). This standard requires a financial asset to be presented at amortized cost basis at the net amount expected to be collected. It also requires that credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. In November 2019, the FASB issued an amendment making this standard effective for annual reporting periods beginning after December 15, 2022 for smaller reporting companies. Early adoption is permitted. The Company ~~is currently evaluating the impact that~~adopted this standard ~~will have~~ on ~~its~~January 1, 2023 with no material impact on the condensed consolidated financial ~~statements~~statements.

Recent Accounting Pronouncements – Not Yet Adopted

In August 2020, the FASB issued Accounting Standards Update 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2020-06”), which reduces the number of accounting models for convertible debt instruments and convertible preferred stock as well as amends the ~~timing of when this standard will be adopted.~~derivatives scope exception for contracts in an entity’s own equity. ASU 2020-06 is effective for the Company on January 1, 2024, with early adoption permitted.

Summary of Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2, “Summary of Significant Accounting Policies” in the ~~2021~~2022 Annual Report on Form 10-K, and there were no significant changes to such policies in the three months ended March 31, ~~2022~~2023 that had a material impact on the Company’s results of operations or financial position.

Table of Contents

3. ~~Acquisition of Quellis~~

~~On January 28, 2021, the Company completed the Quellis Acquisition in accordance with the terms of the Merger Agreement as discussed in Note 1, “~~~~Organization and Operations~~”. Under the terms of the Merger Agreement, the Company issued 555,444 shares of common stock and 50,504 shares of Series X Preferred Stock. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock, subject to certain conditions.

The Company concluded that the Quellis Acquisition was not the acquisition of a business, as substantially all of the fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.

The Company determined that the cost to acquire the Quellis assets was $170.7 million, based on the fair value of the equity consideration issued and including direct costs of the acquisition of $1.8 million. The net assets acquired in connection with the Quellis Acquisition were recorded at their estimated fair values as of January 28, 2021, which is the date the Quellis Acquisition was completed. The following table summarizes the net assets acquired based on their estimated fair values as of January 28, 2021 (in thousands):

Acquired IPR&D

$
164,612
Cash and cash equivalents

8,307
Prepaid expenses and other assets

136
Accounts payable

(1,974)
Accrued liabilities

(400)
Net acquired tangible assets

$
170,681

In the estimation of fair value of the asset purchase consideration, the Company used the carrying value of the cash and cash equivalents, prepaid expenses, accounts payable and accrued liabilities as the most reliable indicator of fair value based on the associated short-term nature of the balances. The remaining fair value was attributable to the acquired IPR&D. As STAR-0215 had not, at the time of the Quellis Acquisition, received regulatory approval in any territory, the cost attributable to the IPR&D was expensed in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss for the three months ended March 31, 2021 as the acquired IPR&D had no alternative future use, as determined by the Company in accordance with U.S. GAAP.

4. Financial Instruments

The tables below present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, ~~2022~~2023 and December 31, ~~2021~~2022, and indicate the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize observable inputs such as quoted prices in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are either directly or indirectly observable, such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs utilize unobservable data points for which there is little or no market data, which require the Company to develop its own assumptions for the asset or liability. There were no transfers between fair value measurement levels during the three months ended March 31, ~~2022~~2023 and ~~2021.~~2022.

~~Table of Contents~~

The Company’s investment portfolio may include fixed income securities that do not always trade on a daily basis. As a result, the pricing services used by the Company apply other available information as applicable through processes such as benchmark yields, benchmarking of like securities, sector groupings and matrix pricing to prepare valuations. The Company validates the prices provided by its third party pricing services by obtaining market values from other pricing sources and analyzing pricing data in certain instances. The Company also invests in certain reverse repurchase agreements which are collateralized by deposits in the form of U.S. Government Securities and Obligations for an amount no less than 102% of their value. The Company does not record an asset or liability for the collateral as the Company is not permitted to sell or re-pledge the collateral. The collateral has at least the prevailing credit rating of U.S. Government Treasuries and Agencies. The Company utilized a third-party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the reverse repurchase agreements on a daily basis.

The Company accounted for warrants to purchase its stock pursuant to Accounting Standards Codification (“ASC”) Topic 470, Debt, and ASC Topic 480, Distinguishing Liabilities from Equity, and classifies warrants for common stock and preferred stock as liabilities or equity. The warrants classified as liabilities are reported at their estimated fair value and any changes in fair value are reflected in research and development expense. The warrants classified as equity are reported at their estimated fair value with no subsequent remeasurement.

Below is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):

As of March 31, 2022

Quoted

Prices

Significant

Significant

in Active

Observable

Unobservable

Markets

Inputs

Inputs


(Level 1)

(Level 2)

(Level 3)

Total
Assets:

Cash equivalents:

Money market funds

$
8,145

$
—

$
—

$
8,145
Corporate debt securities

—

4,396

—

4,396
Commercial paper

—

3,996

—

3,996
Reverse repurchase agreements

—

3,000

—

3,000
Short term investments

Corporate debt securities

—

17,121

—

17,121
Commercial paper

—

5,980

—

5,980
Yankee securities

—

4,029

—

4,029
Treasury bills

1,999

—

—

1,999
Reverse repurchase agreements

—

37,000

—

37,000
Total

$
10,144

$
75,522

$
—

$
85,666

As of December 31, 2021

Quoted

Prices

Significant

Significant

in Active

Observable

Unobservable

Markets

Inputs

Inputs


(Level 1)

(Level 2)

(Level 3)

Total
Assets:

Cash equivalents:

Money market funds

$
1,853

$
—

$
—

$
1,853
Short-term investments:

Reverse repurchase agreements

—

39,000

—

39,000
Total

$
1,853

$
39,000

$
—

$
40,853

The carrying amounts reflected in the unaudited condensed consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. Items measured at fair value on a recurring basis include cash equivalents and short-term investments as of March 31, 2022 and December 31, 2021.


	As of March 31, 2023
	Quoted
	Prices		Significant		Significant
	in Active		Observable		Unobservable
	Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash equivalents:
Money market funds	$	1,715	$	—	$	—	$	1,715
Reverse repurchase agreements		—		69,000		—		69,000
Treasury bills		6,973		—		—		6,973
Short-term investments:
Corporate debt securities		—		6,075		—		6,075
Treasury bills		4,952		—		—		4,952
Total	$	13,640	$	75,075	$	—	$	88,715

Table of Contents


	As of December 31, 2022
	Quoted
	Prices		Significant		Significant
	in Active		Observable		Unobservable
	Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash and cash equivalents:
Money market funds	$	1,944	$	—	$	—	$	1,944
Short term investments
Corporate debt securities		—		16,445		—		16,445
Yankee securities		—		1,999		—		1,999
Bonds		—		2,988		—		2,988
Treasury bills		5,980		—		—		5,980
Reverse repurchase agreements		—		178,500		—		178,500
Total	$	7,924	$	199,932	$	—	$	207,856

5. 4.Short-Term Investments

The following table summarizes the short-term investments held at March 31, ~~2022~~2023 and December 31, ~~2021~~2022 (in thousands):


			Gross Unrealized		Gross Unrealized						Gross Unrealized		Gross Unrealized
	Amortized Cost		Gains		Losses		Fair Value		Amortized Cost		Gains		Losses		Fair Value
March 31, 2022
March 31, 2023
Corporate debt securities	$	17,157	$	—	$	(36)	$	17,121	$	6,082	$	—	$	(7)	$	6,075
Commercial paper		5,987		—		(7)		5,980
Yankee securities		4,039		—		(10)		4,029
Treasury bills		1,999		—		—		1,999		4,949		3		—		4,952
Reverse repurchase agreements		37,000		—		—		37,000
Total	$	66,182	$	—	$	(53)	$	66,129	$	11,031	$	3	$	(7)	$	11,027


			Gross Unrealized		Gross Unrealized						Gross Unrealized		Gross Unrealized
	Amortized Cost		Gains		Losses		Fair Value		Amortized Cost		Gains		Losses		Fair Value
December 31, 2021
December 31, 2022
Corporate debt securities									$	16,508	$	—	$	(63)	$	16,445
Treasury bills										5,983		—		(3)		5,980
Yankee securities										2,000		—		(1)		1,999
U.S. agency bonds										3,000		—		(12)		2,988
Reverse repurchase agreements	$	39,000	$	—	$	—	$	39,000		178,500		—		—		178,500
Total	$	39,000	$	—	$	—	$	39,000	$	205,991	$	—	$	(79)	$	205,912

The contractual maturities of all short-term investments held at March 31, ~~2022~~2023 and December 31, ~~2021~~2022 were one year or less. There were 153 and 16 short-term investments in an unrealized loss position atwith aggregate values of $6.2 million and $25.6 million as of March 31, 2023 and December 31, 2022, ~~with an aggregate value of $26.3 million.~~respectively. These investments were in a loss position for less than 12 months and the Company considered the loss to be temporary in nature. The Company considered the decline in market value for these securities to be primarily attributable to economic and market conditions. As of March 31, ~~2022,~~2023, the Company did not intend to sell, and it was not likely that the Company would be required to sell, the investments that were in an unrealized loss position before recovery of their amortized cost basis. Accordingly, the Company did not recognize any other-than-temporary impairments related to its short-term investments in an unrealized loss position. ~~There were no short-term investments in an unrealized loss position at December 31, 2021.~~

Table of Contents

Gross realized gains and losses on the sales of short-term investments are included in other income, net. Unrealized holding gains or losses for the period that have been included in accumulated other comprehensive income, as well as gains and losses reclassified out of accumulated other comprehensive income into other income, net, were not material to the Company’s condensed consolidated results of operations. The cost of investments sold or the amount reclassified out of the accumulated other comprehensive income into other income, net is based on the specific identification method for purposes of recording realized gains and losses. All proceeds in the three-month periods ended March 31, ~~2022~~2023 and ~~2021~~2022 related to maturities of underlying investments. The gains on proceeds from maturities of short-term investments were not material to the Company’s condensed consolidated results of operations for the three months ended March 31, ~~2022~~2023 and ~~2021.~~2022.

6.5.Accrued Expenses

Accrued expenses consisted of the following (in thousands):


	March 31,		December 31,		March 31,		December 31,
	2022		2021		2023		2022
Accrued contracted costs	$	2,073	$	760	$	2,818	$	2,822
Accrued compensation		713		1,958		974		3,373
Accrued professional fees		638		268		955		588
Accrued other		428		295		409		407
Accrued milestones						—		500
Total	$	3,852	$	3,281	$	5,156	$	7,690

~~Table of Contents~~

7.6.Commitments

~~Future minimum payments required under the Company’s non-cancelable operating lease as of March 31, 2022 are summarized as follows (in thousands):~~

Period Ending December 31,

Amount
2022

$
188
Total lease payments

$
188
Less: imputed interest

(4)
Total operating lease liabilities

$
184

~~Rent expense was $0.2 million for each of the three months ended March 31, 2022 and 2021. Lease payments were $0.2 million for each of the three months ended March 31, 2022 and 2021, respectively.~~

On January 28, 2022, the Company entered into a sublease agreement (the “Sublease”) with Grant Thornton LLP ~~(the “Sublandlord”),~~ for new office space to replace its existing office space. The Sublease commenced on May 1, 2022 and will end on July 31, 2024 (or on such earlier date as the term may cease or expire as set forth in the ~~Sublease ). The Sublease will increase the future~~Sublease).

Future minimum payments inrequired under the ~~table above from approximately~~Company’s Sublease as of March 31, 2023 are summarized as follows (in thousands):


Period Ending December 31,	Amount
2023		446
2024		395
Total lease payments	$	841
Less: imputed interest		(47)
Total operating lease liabilities	$	794

Rent expense was $0.2 million ~~to approximately $1.6 million.~~for each of the three months ended March 31, 2023 and 2022. Lease payments were $0.2 million for each of the three months ended March 31, 2023 and 2022.

8.7.Stockholders’ Equity

Preferred Stock

Under the Company’s Restated Certificate of Incorporation, the Company has 5,000,000 shares of preferred stock authorized for issuance, with a $0.001 par value per share. Preferred stock may be issued from time to time in one or more series, each series to have such terms as stated or expressed in the resolutions providing for the issue of such series adopted by the Board of Directors of the Company. Preferred stock which may be redeemed, purchased or acquired by the Company may be reissued except as otherwise provided by law. As of March 31, 2022, the Company had 31,455 shares of Series X Preferred Stock outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock is 5,242,501. Refer to Note 1 , “~~Organization and Operations”~~ ~~regarding the Company’s issuance of Series X Preferred Stock in January 2021 and February 2021.~~

~~Outstanding Warrants~~

~~The following table presents information about warrants that are issued and outstanding at March 31, 2022:~~

Year Issued

Equity Instrument

Warrants Outstanding

Exercise Price

Date of Expiration
2018

Common Stock

699,962

$
72.00

6/21/2023
2019

Common Stock

331,858

$
37.50

2/7/2024
2021

Common Stock

498,356

$
2.10

12/14/2030
Total

1,530,176

Weighted average exercise price

$
41.75

Weighted average life in years



3.80

Table of Contents

In January, 2021 the Company into a Stock Purchase Agreement (the “Purchase Agreement”) with certain institutional and accredited investors. Pursuant to the Purchase Agreement, the Company sold an aggregate of 35,573 shares of Series X Preferred Stock for gross proceeds of approximately $110.0 million, and net proceeds of $104.3 million. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock. On January 3, 2023, a holder of Series X Preferred Stock elected to convert 348 shares of Series X Preferred Stock into 57,910 shares of common stock. As of March 31, 2023, the Company had 31,107 shares of Series X Preferred Stock outstanding and the number of shares of underlying common stock issuable upon conversion of the Series X Preferred Stock was 5,184,591.

Outstanding Warrants

The following table presents information about warrants that are issued and outstanding at March 31, 2023:


Year Issued	Equity Instrument	Warrants Outstanding	Exercise Price		Date of Expiration
2018	Common Stock	699,962	$	72.00	6/21/2023
2019	Common Stock	331,858	$	37.50	2/7/2024
Total		1,031,820
Weighted average exercise price			$	60.90
Weighted average life in years					0.43

9. 8.Reserved for Future Issuance

The Company has reserved for future issuance the following shares of common stock:


	March 31,	December 31,	March 31,	December 31,
	2022	2021	2023	2022
Series X Preferred Stock	5,242,501	5,242,501	5,184,591	5,242,501
Options outstanding to purchase common stock			2,562,234	2,253,431
Reserve under the 2015 Stock Incentive Plan and the 2022 Inducement Stock Incentive Plan			1,082,245	1,013,520
Warrants for the purchase of common stock	1,530,176	1,530,380	1,031,820	1,530,176
Options outstanding to purchase common stock	1,962,650	1,346,733
Options available for future issuance to purchase common stock	1,332,716	1,633,736
Shares reserved for the employee stock purchase plan	36,982	30,904	43,060	36,982
Total	10,105,025	9,784,254	9,903,950	10,076,610

~~10.~~ 9.Stock Incentive Plans

A summary of the Company’s stock option activity and related information follows:


				Weighted						Weighted
				Average	Aggregate					Average	Aggregate
		Weighted-		Remaining	Intrinsic			Weighted-		Remaining	Intrinsic
		Average		Contractual	Value			Average		Contractual	Value
	Shares	Exercise Price		Term (years)	(in thousands)		Shares	Exercise Price		Term (years)	(in thousands)
Outstanding at December 31, 2021	1,346,733	$	22.25	9.02	$	168
Outstanding at December 31, 2022							2,253,431	$	15.43	8.57	$	9,733
Granted	650,150	$	6.48				474,250	$	13.35
Exercised							(22,472)	$	1.65
Cancelled or forfeited	(34,233)	$	17.56				(142,975)	$	13.52
Outstanding at March 31, 2022	1,962,650	$	17.11	9.14	$	381
Vested and exercisable at March 31, 2022	175,632	$	58.41	7.27	$	228
Outstanding at March 31, 2023							2,562,234	$	15.27	8.57	$	7,370
Vested and exercisable at March 31, 2023							835,970	$	23.94	7.87	$	1,468
Vested and expected to vest at March 31, 2023							2,562,234	$	15.27	8.57	$	7,370

~~There were 0~~The intrinsic value of stock options exercised in the three months ended March 31, ~~2022 and 2021.~~2023 was $0.3 million. There were no stock options exercised in the three months ended March 31, 2022. The total grant date fair value of stock options vested for the three months ended March 31, 2023 and 2022 ~~and 2021~~ was ~~$0.6~~$1.5 million and ~~$0.5~~$0.6 million, respectively. The weighted-average grant date fair value of options granted to employees and non-employees for the three months ended March 31, 2023 and 2022 was $8.49 and ~~2021 was~~ $4.05, ~~and $9.00,~~ respectively.

Table of Contents

At March 31, ~~2022,~~2023, the total unrecognized compensation expense related to unvested stock option awards was ~~$11.9~~$11.2 million. The Company expects to recognize that cost over a weighted-average period of approximately ~~3.0~~2.6 years.

On February 1, 2023, the Company issued stock options exercisable for 855,000 shares of common stock to certain officers of the Company. Subsequently one officer of the Company left and consequently of these stock options only options exercisable for 755,000 shares remain outstanding. The stock options issued on February 1, 2023 were issued subject to stockholder approval of the authorization of additional shares of common stock for issuance under the Company’s 2015 Amended and Restated Stock Incentive Plan on or before January 31, 2024. Due to this stockholder approval requirement, these stock options are not considered granted as of March 31, 2023. The Company is seeking stockholder approval of an additional 4,300,000 shares for this plan at the Company’s 2023 Annual Meeting of Stockholders, which is scheduled for June 2, 2023. Stockholder approval of this proposal would result in the officer stock option grants discussed above being considered granted.

On February 17, 2022, the Company’s Board of Directors adopted the 2022 Inducement Stock Incentive Plan (the “Inducement Plan”). The Inducement Plan provides for the grant of nonstatutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards ~~(collectively, the “stock awards”)~~ with respect to an aggregate of 300,000 shares of the Company’s common stock. On January 31, 2023, the Company's Board of Directors approved an amendment to the Inducement Plan to increase the number of shares of common stock authorized for issuance thereunder from 300,000 shares of common stock to 700,000 shares of common stock. Awards under the Inducement Plan may only be granted to persons who (a) were not previously an employee or director of the Company or (b) are commencing employment with the Company following a bona fide period of non-employment, in either case as an inducement material to the individual’s entering into employment with the Company and in accordance with the requirements of Nasdaq Stock Market Rule 5635(c)(4). As of March 31, ~~2022, there~~2023, options to purchase 232,800 shares of common stock have been ~~0 grants issued~~granted under the Inducement Plan, ~~and 300,000 shares of common stock remained available for future issuance.~~which are included in the table above.

~~11.~~ 10.Subsequent Events

The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the financial statements to provide additional evidence for certain estimates and to identify matters that require additional disclosure. Subsequent events have been evaluated as required.

1516

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2021 ,~~2022, or the ~~2021~~2022 Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our plans and strategy for our business, includes forward-looking statements that involve risks and uncertainties. You should review the sections entitled “Risk Factors” and “Summary of the Material Risks Associated with Our Business” in our ~~2021~~2022 Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. This section provides additional information regarding our business, current developments, results of operations, cash flows, financial condition, contractual commitments and critical accounting policies and estimates that require significant judgement and have the most potential impact on our unaudited condensed consolidated financial statements. This discussion and analysis is intended to better allow investors to view the Company from management’s perspective.

Overview

We are a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics. Our mission is to bring hope with life-changing therapies to patients and families that are affected by rare and niche allergic and immunological diseases. Our lead product candidate is STAR-0215, a potential best-in-class monoclonal antibody inhibitor of plasma kallikrein in ~~preclinical~~clinical development for the treatment of hereditary angioedema, or HAE, a rare, debilitating and potentially life-threatening disease. STAR-0215 has the potential to be the most patient-friendly chronic treatment option for HAE, based on the ~~preclinical~~ data generated to date and the existing HAE treatment landscape.

The treatment options for patients with HAE have improved in recent years, however, there is remaining unmet medical need and the global market for HAE therapy is strong and growing. The goal for STAR-0215 is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE. Our vision for STAR-0215 is to become the first-choice preventative treatment for HAE with administration every three or six months with the goal of normalizing the lives of people living with HAE. Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling. STAR-0215 is currently in clinical development. We submitted an investigational new drug application, or IND, for STAR-0215 in June 2022 and the FDA cleared our IND for STAR-0215 in July 2022.

We initiated a Phase 1a clinical trial in August 2022 and we announced preliminary results in December 2022. We presented additional initial results from the trial through the first 84 days of follow up at the American Academy of Allergy, Asthma, and Immunology conference in February 2023. This Phase 1a randomized, double-blind, placebo-controlled single ascending dose clinical trial evaluated the safety, pharmacokinetics, or PK, and pharmacodynamics, or PD, of STAR-0215 at a single U.S. center. Healthy subjects received a single dose of STAR-0215 or placebo in three cohorts of 100mg, 300mg, and 600mg administered subcutaneously. STAR-0215 was well-tolerated at all dose levels. Additionally, there were no clinically significant changes in laboratory assessments and there were no treatment-emergent anti-drug antibodies detected. STAR-0215 demonstrated rapid and sustained drug levels with dose-dependent PK and an estimated half-life of up to 117 days. Sustained target engagement was seen with inhibition of plasma kallikrein consistent with levels associated with clinical benefit for at least three months. The initial results from the Phase 1a trial support investigating STAR-0215 in HAE patients and also suggest that there could be an opportunity to dose STAR-0215 less frequently than every three months. As a result, we are evaluating the potential for 6-month dosing with additional healthy subject cohorts in the Phase 1a trial with initial results expected in the fourth quarter of 2023. The final results from the first three cohorts in the Phase 1a trial are also expected in the fourth quarter of 2023.

The initial Phase 1a results support STAR-0215’s target profile as a long-acting plasma kallikrein inhibitor and support advancing STAR-0215 to a Phase 1b/2 trial called ALPHA-STAR, or Astria Long-acting Prophylaxis for Hereditary Angioedema: STAR-0215, which we initiated in February 2023. This global, multi-center, open-label, single and multiple dose proof-of-concept clinical trial in people with HAE, is evaluating safety, tolerability, HAE attack rate, PK, PD, and quality of life in patients three and six months after STAR-0215 administration. We are currently enrolling patients in the trial and have initiated administration of STAR-0215 to enrolled patients. We expect to report initial data from single and multiple dose cohorts in the trial in mid-2024.

Table of Contents

In May 2023, we presented new human mechanistic modeling data at the 13^th C1-Inhibitor Deficiency & Angioedema Workshop. These data support the potential for STAR-0215 to be administered once every three or six months for robust suppression of HAE attacks.

In January 2021, we acquired Quellis Biosciences, Inc., or Quellis, including the STAR-0215 program, and announced a private placement that, upon closing in February 2021, resulted in gross proceeds to us of approximately $110.0 million before deducting placement agent and other offering expenses, which we refer to as the February 2021 Financing. In November 2020, after we stopped the development of our edasalonexent program as a potential treatment for Duchenne Muscular Dystrophy, or DMD,we decided to explore and evaluate strategic options. The acquisition of Quellis was the result of our evaluation of strategic options.

In September 2021, we formally changed our name to Astria Therapeutics, Inc. from Catabasis Pharmaceuticals, Inc. The name “Astria” originates from the Greek word for star, demonstrating our commitment to patients who serve as our guiding stars.

HAE is a rare, debilitating and potentially life-threatening disease. The treatment options for patients with HAE have improved, however, there is remaining unmet medical need and the global market for HAE therapy is strong and growing. The vision for our lead program, STAR-0215, is to develop a best-in-class monoclonal antibody inhibitor of plasma kallikrein able to provide long-acting, effective attack prevention for HAE with dosing once every three months or longer. Targeted plasma kallikrein inhibition can prevent HAE attacks by suppressing the pathway that generates bradykinin and causes excessive swelling. STAR-0215 is currently in preclinical development and we expect to submit an Investigational New Drug application, or IND, for STAR-0215 in mid-2022 and plan to initiate a Phase 1a clinical trial shortly thereafter with initial results anticipated by year end 2022. We believe that this clinical trial has the opportunity to establish proof of concept for the differentiated profile of STAR-0215. We expect the Phase 1a clinical trial to be conducted in a single center with healthy volunteers and evaluate several single escalating dose cohorts with subcutaneous administration. Our goals for this trial with STAR-0215 are to demonstrate safety and tolerability, establish the prolonged half-life, demonstrate the duration of inhibition of plasma kallikrein activity and to refine dose and dosing regimen for studies in HAE patients. Assuming positive data from the Phase 1a trial, we plan to initiate a Phase 1b/2 trial in patients with HAE in 2023. We expect the Phase 1b/2 trial, if initiated, would be a randomized, placebo-controlled, global multi-center trial in HAE patients, and that the primary goals for the trial would be to demonstrate safety and tolerability, establish prolonged half-life, demonstrate inhibition of plasma kallikrein activity, and provide an initial assessment of the impact of STAR-0215 on HAE attack rate.

~~Table of Contents~~

Our vision for STAR-0215 is supported by preclinical data showing potent inhibition of the production of bradykinin by plasma kallikrein and a long plasma half-life that could potentially enable patients to dose less frequently. Multiple experiments have confirmed that STAR-0215 is approximately 10-fold more potent than lanadelumab, a monoclonal antibody inhibitor of plasma kallikrein commercialized under the name TAKHZYRO and an approved preventative treatment for HAE, in inhibiting bradykinin production. In cynomolgus monkey studies, lanadelumab was observed to have a half-life of approximately 10 days, which is consistent with what has been reported in U.S. Food and Drug Administration, or FDA, review documents and publications for lanadelumab in non-human primates. STAR-0215 was administered at the same dose as lanadelumab and the observed half-life was approximately 34 days, which is about a three to four-fold longer half-life than observed for lanadelumab. We believe this could translate to a half-life of several months for STAR-0215 in humans. If this longer half-life is demonstrated in clinical trials, it has the potential to enable dosing once every three months or longer.

We presented preclinical data from the STAR-0215 program at the American College of Allergy, Asthma and Immunology, or ACAAI, Annual Scientific Meeting in November 2021, demonstrating the high potency of STAR-0215 for binding to and inhibition of plasma kallikrein on a different site than lanadelumab and supporting the ability of YTE technology to extend half-life. YTE modifications in STAR-0215 are designed to enable a longer duration of action. In cynomolgus monkeys dosed with STAR-0215, the YTE modifications protected STAR-0215 from antibody clearance leading to a more than three-fold increase in plasma half-life compared to an antibody without the YTE modifications. Additional preclinical data presented at the American Academy of Allergy, Asthma, and Immunology, or AAAAI, Annual Meeting in February 2022 demonstrated how STAR-0215 binds to plasma kallikrein. At the Fc Receptor and IgG Targeted Therapies Conference in AprilOn December 19, 2022, we presented pharmacokinetic modeling data supporting that STAR-0215 has the potential to effectively inhibit plasma kallikrein and prevent HAE attacks with subcutaneous dosing volumes appropriate for a self-injectable device dosed once every three months or longer. The preclinical and modeling data to date suggest that at equal or potentially lower doses STAR-0215 would have a significantly longer durationclosed an underwritten public offering of action than lanadelumab and could result in STAR-0215 being an effective preventative therapy for patients with HAE due to inhibition of the pathologic activity of plasma kallikrein for an extended time period.

~~January 2021 Quellis Acquisition and February 2021 Financing~~

In January 2021, we acquired Quellis pursuant to an Agreement and Plan of Merger, or the Merger Agreement, by and among us, Cabo Merger Sub I, Inc., a Delaware corporation and our wholly owned subsidiary, or the First Merger Sub, Cabo Merger Sub II, LLC, a Delaware limited liability company and our wholly owned subsidiary, or the Second Merger Sub, and Quellis, or the Quellis Acquisition. Pursuant to the Merger Agreement, the First Merger Sub merged with and into Quellis, pursuant to which Quellis was the surviving entity and became a wholly owned subsidiary of ours, or the First Merger. Immediately following the First Merger, Quellis merged with and into the Second Merger Sub, pursuant to which the Second Merger Sub was the surviving entity, or the Second Merger and, together with the First Merger, the Merger. Under the terms of the Merger Agreement, at the closing of the Merger, we issued to the Quellis stockholders 555,44410,445,050 shares of our common stock, ~~and 50,504 shares~~including the full exercise of newly designated Series X Preferred Stock (as described below). In addition, we assumed outstanding Quellis stock options, which became options for 55,414 shares of our common stock, and assumed a warrant exercisable for Quellis common stock, which became a warrantthe underwriters’ option to purchase 2,805 shares of Series X Preferred Stock at an exercise price of $341.70 per share, and a warrant to purchase 30,856 shares of our common stock at an exercise price of $2.10 per share. Upon stockholder approval of the Conversion Proposal (as defined below) on June 2, 2021, the warrant to purchase Series X Preferred Stock was converted into the right to purchase 467,5001,362,397 shares of our common stock, at a price of $11.01 per share, ~~exercise price of $2.10 per share. We concluded that~~which we refer to as the ~~Quellis Acquisition was not the acquisition of a business, as substantially all~~December 2022 Financing. The gross proceeds of the ~~fair value of the non-monetary assets acquired was concentrated in a single identifiable asset, STAR-0215.~~

~~In January 2021, we also entered into a Stock Purchase Agreement, or the Purchase Agreement, with certain institutional~~December 2022 Financing were approximately $115.0 million, before deducting underwriting discounts and accredited investors pursuant to which we sold an aggregate of 35,573 shares of Series X Preferred Stock for an aggregate purchase price of $110.0 million, or the February 2021 Financing. Our stockholders approved the conversion of the Series X Preferred Stock into shares of common stock in accordance with Nasdaq Listing Rule 5635(a), or the Conversion Proposal, at our Annual Meeting of Stockholders on June 2, 2021. On the fourth business day after the approval of the Conversion Proposal, each share of Series X Preferred Stock automatically converted into 166.67 shares of common stock, subject to certain beneficial ownership limitations, including that a holder of Series X Preferred Stock is prohibited from converting shares of Series X Preferred Stock into shares of common stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (as of March 31, 2022, these percentages are set at 4.99% to 9.99%commissions and can be adjusted by the holder to a number between 4.99% and 19.99%) of the total number of shares of common stock issued and outstanding immediately after giving effect to such conversion. Shares of Series X Preferred Stock not converted automatically are thereafter subject to conversion at the option of the holder, subject to certain beneficial ownership limitations. As of April 29, 2022, 54,622 shares of Series X Preferred Stock have been converted into 9,103,664

~~Table of Contents~~

shares of common stock and 31,455 shares of Series X Preferred Stock remained outstanding. Each share of Series X Preferred Stock is convertible into 166.67 shares of common stock and therefore the number of shares of underlying common stock issuable upon conversion of the outstanding shares Series X Preferred Stock is 5,242,501. Outstanding shares of Series X Preferred Stock are subject to conversion at the option of the holder.

~~Reverse Stock Split~~

On August 4, 2021, our Board of Directors approved a reverse stock split of our outstanding shares of common stock at a ratio of one-for-six (1:6). The reverse stock split became effective on August 19, 2021. The reverse stock split was approved by our stockholders at our Annual Meeting of Stockholders on June 2, 2021. All share and per share amounts of the common stock included in this Quarterly Report on Form 10-Q, including in the accompanying unaudited condensed consolidated financial statements, have been retrospectively adjusted to give effect to the reverse stock split for all periods presented, including reclassifying an amount equal to the reduction in par value to additional paid-in capital. As of April 29, 2022, we had 13,016,955 shares of outstanding common stock and approximately 31,455 shares of outstanding Series X Preferred Stock, which we issued in the Quellis Acquisition and the February 2021 Financing, which are convertible into 5,242,501 shares of common stock.other offering expenses.

Financial Overview

Our business is almost entirely dependent on the success of STAR-0215, which is in the ~~preclinical stage~~early clinical stages of development, and has only produced results in a Phase 1a clinical trial, preclinical and nonclinical settings. Our ~~net~~ losses from operations were ~~$15.3~~$13.5 million and ~~$170.1~~$15.4 million ~~(including $164.6 million of in-process research and development expenses)~~ for the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, respectively. As of March 31, ~~2022,~~2023, we had an accumulated deficit of ~~$471.1~~$518.8 million. We have financed our operations to date primarily through private placements of preferred stock before we became a public company, ~~and~~ our private placement of preferred stock in the February 2021 Financing and registered offerings of our common stock, ~~and~~including our at-the-market offering programs, and have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and clinical development programs. As of March 31, ~~2022,~~2023, we had ~~$112.8~~$213.3 million in cash, cash equivalents and short-term investments. WeBased on our current operating plan, we expect that our ~~existing~~ cash, cash equivalents and short-term investments as of March 31, 2023 are sufficient to ~~support~~fund our operating expenses and capital ~~expenditures~~expenditure requirements through ~~2023.~~the first half of 2025. Advancing the development of STAR-0215 or any future product candidates will require a significant amount of capital. Our existing cash, , cash equivalents and short-term investments will not be sufficient to fund STAR-0215 or any future product candidates through regulatory approval. We will need to obtain substantial additional funding to complete the development and commercialization of STAR-0215 or any future product candidates and support our continuing operations, future clinical trials and expansion of our pipeline. Furthermore, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional financing to fund our long-term operations sooner than planned. See the section titled “Liquidity and Capital Resources” below for additional information.

Research and Development Expenses

Research and development expenses consist primarily of costs incurred for our research activities, including our drug discovery efforts, and the development of our product candidates, which include:

●

employee-related expenses including salaries, benefits and stock-based compensation expense;

●

expenses incurred under agreements with third parties, including contract research organizations that conduct clinical trials and research and development and preclinical activities on our behalf;

●

the cost of consultants;

●

the cost of lab supplies and acquiring, developing and manufacturing study materials; and

●

facilities and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies.

Research and development costs are expensed as incurred. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized. The capitalized amounts are expensed as the related goods are delivered or the services are performed.

We typically use our employee, consultant and infrastructure resources across our development programs. We track outsourced development costs by product candidate or development program, but we do not allocate personnel costs, other internal costs or external

~~Table of Contents~~

consultant costs to specific product candidates or development programs. We record our research and development expenses net of any research and development tax incentives we are entitled to receive from government authorities.

Table of Contents

The following table summarizes our research and development expenses by program (in thousands):


	Three Months Ended March 31,				Three Months Ended March 31,
	2022		2021		2023		2022
STAR-0215	$	6,269	$	458	$	4,140	$	6,269
Edasalonexent		64		456
Other research programs		301		—
Other programs						710		365
Costs not directly allocated to programs:
Employee expenses including cash compensation, benefits and stock-based compensation		1,375		1,227		2,746		1,375
Consultants and professional expenses, including stock-based compensation						308		2,226
Facilities		80		88		67		80
Consultants and professional expenses, including stock-based compensation		2,226		276
Other		43		88		62		43
Total costs not directly allocated to programs		3,724		1,679		3,183		3,724
Total research and development expenses	$	10,358	$	2,593	$	8,033	$	10,358

Based on the results of the Phase 3 PolarisDMD trial of edasalonexent for the treatment of DMD, in October 2020 we stopped all activities related to the development of edasalonexent, including the ongoing GalaxyDMD open-label extension trial, and wound down substantially all activities related to edasalonexent by mid-2021.

We expect to incur significant research and development expenses in the year ending December 31, ~~2022~~2023, and in future periods in connection with the ~~preclinical~~clinical trials and ~~clinical~~other activities related to the development of STAR-0215. Because of this, we expect that our research and development expenses over the next several quarters will be higher than the prior year periods. Development of STAR-0215 and any future product candidates is highly uncertain and we cannot reasonably estimate at this time the nature, timing and costs of the efforts that would be necessary to complete the development of any such product candidates. We are also unable to predict when, if ever, material net cash inflows would commence from STAR-0215 or any ~~such~~other future product candidates. This is due to the fact that we would need to raise substantial additional capital to fund the clinical development of any such product candidates and the numerous risks and uncertainties associated with developing and commercializing product candidates, including the uncertainties of:

●

establishing an appropriate safety profile with IND-enabling toxicology studies;

●

successful design of, enrollment in, and completion of clinical trials;

●

feedback from the FDA and foreign regulatory authorities on planned trial designs, pre-clinical studies and manufacturing capabilities and plans;

●

changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products;

●

receipt of marketing approvals from applicable regulatory authorities;

●

establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;

●

obtaining and maintaining patent and trade secret protection and regulatory exclusivity;

●

launching commercial sales, if we are able to obtain marketing approval, whether alone or in collaboration with others, and our ability to compete successfully with other products; and

●

a continued acceptable safety profile following approval.

A change in the outcome of any of these variables with respect to the development of STAR-0215 or any future product candidate would significantly change the costs and timing associated with the development of that product candidate.

General and Administrative Expenses

General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation, for personnel in executive, finance, accounting, ~~commercial,~~pre-commercial, business development, information technology, legal and human resources functions. Other significant costs include facility costs not otherwise included in research and development expenses, legal fees relating to patent and corporate matters, and fees for accounting and consulting services.

~~Table of Contents~~

We anticipate that ~~in the near term~~ our general and administrative expenses will ~~remain relatively consistent with~~increase from their current levels ~~although~~ as we continue to grow our company, develop STAR-0215 and potentially expand our pipeline to include other product ~~candidates, our general and administrative expenses may increase.~~

~~Acquired In-process Research and Development Expense~~

Acquired in-process research and development (“IPR&D”) expense resulted from the Quellis Acquisition in January 2021. The acquisition cost allocated to acquire IPR&D with no alternative future use was recorded as expense at the acquisition date and no additional IPR&D expense relating to the Quellis Acquisition is expected to be reported in future periods.

~~Reduction in Workforce~~

In December 2020, following the decision to stop development of edasalonexent, we announced that we were reducing our workforce during the quarter ended December 31, 2020. The reduction resulted in total expenses for employee severance and employee benefits of $0.6 million, of which $0.2 million was recorded during the three months ended March 31, 2021. As of March 31, 2022, all severance and employee benefits related to the reduction of workforce has been paid.candidates.

Other Income, ~~(Expense),~~ Net

Other income, ~~(expense),~~ net consists of interest income earned on our cash, cash equivalents and short-term investments and net amortization expense on short-term investments, and gains and losses related to foreign currency fluctuations.

Table of Contents

Critical Accounting ~~Policies and Significant Judgments and~~ Estimates

This discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with United States generally accepted accounting principles. We believe that several accounting policies are important to understanding our historical and future performance. We refer to these policies as critical because these specific areas generally require us to make judgments and estimates about matters that are uncertain at the time we make the estimate, and different estimates—which also would have been reasonable—could have been used. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and other market-specific or other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

During the three months ended March 31, ~~2022,~~2023, there were no material changes to our critical accounting policies as reported in our ~~2021~~2022 Annual Report on Form 10-K.

~~Table of Contents~~

Results of Operations

We anticipate that our results of operations may fluctuate for the foreseeable future due to several factors, such as the progress of our research and development efforts and the timing and outcome of regulatory submissions.

Comparison of the Three Months Ended March 31, ~~2022~~2023 and ~~2021~~2022

The following table summarizes our results of operations for the three months ended March 31, ~~2022~~2023 and ~~2021,~~2022, together with the dollar change in those items (in thousands):


	Three Months Ended March 31,				Period-to-		Three Months Ended March 31,				Period-to-
	2022		2021		Period Change		2023		2022		Period Change
Operating expenses:
Research and development	$	10,358	$	2,593	$	7,765	$	8,033	$	10,358	$	(2,325)
General and administrative		5,020		2,880		2,140		5,460		5,020		440
Acquired in-process research and development		—		164,612		(164,612)
Total operating expenses		15,378		170,085		(154,707)		13,493		15,378		(1,885)
Loss from operations		(15,378)		(170,085)		154,707		(13,493)		(15,378)		1,885
Other income, net		55		1		54		2,305		55		2,250
Net loss	$	(15,323)	$	(170,084)	$	154,761	$	(11,188)	$	(15,323)	$	4,135

Research and Development Expenses

Research and development expenses ~~increased~~decreased by ~~$7.8~~$2.3 million to $8.0 million for the three months ended March 31, 2023 from $10.4 million for the three months ended March 31, 2022, ~~from $2.6 million for the three months ended March 31, 2021, an increase~~a decrease of ~~299%~~22%. The ~~substantial increase~~decrease in research and development expenses was primarily attributable to a ~~$5.8~~$2.1 million ~~increase~~decrease in direct costs to support ~~preclinical~~ development of the STAR-0215 program, and a ~~$2.0~~$1.9 million ~~increase to~~decrease in professional service expenses primarily due to expense recognized on vested warrants ~~inherited~~ in ~~the Quellis Acquisition as described in Note 1, “~~~~Organization and Operations~~~~”, a $0.3 million increase in other research and programs, and a $0.1 million increase in employee expenses. These increases were offset by a $0.4 million~~2022. The decrease in costs to support development of the ~~edasalonexent~~STAR-0215 program is due to ~~stopping all~~timing of the work performed to submit our IND in the first quarter of 2022, with costs to support clinical operations in the first quarter of 2023 not yet being significant enough to result in an increase in costs to support development ~~activities associated with~~of the ~~program.~~STAR-0215 program as compared to the first quarter of 2022. These decreases were partially offset by a $1.3 million increase in employee expenses and a $0.4 million increase in costs for other research programs. As noted above, we expect that our research and development expenses over the next several quarters will be higher than prior periods.

General and Administrative Expenses

General and administrative expenses increased by ~~$2.1~~$0.4 million to $5.5 million for the three months ended March 31, 2023 from $5.0 million for the three months ended March 31, 2022, ~~from $2.9 million for the three months ended March 31, 2021,~~ an increase of ~~74%~~9%. The increase was attributable to a ~~$0.7~~$0.3 million increase in employee-related costs and a $0.3 million increase in professional services ~~expense primarily due to new product planning and business development activities,~~expense. These costs were partially offset by a ~~$0.6~~$0.1 million ~~increase~~decrease in ~~employee related costs, a $0.5 million increase in stock-based compensation~~insurance expense ~~a $0.2 million increase in our Delaware franchise tax fee,~~ and a $0.1 million ~~increase~~decrease in ~~insurance expense.~~general office expenses.

~~Acquired In-process Research and Development Expense~~20

Acquired IPR&D expense was $164.6 million for the three months ended March 31, 2021. Acquired IPR&D expense resulted from the Quellis Acquisition in January 2021. The acquisition cost allocated to acquire IPR&D with no alternative future use was recorded as an expense asTable of ~~the closing date of the Quellis Acquisition. No acquired IPR&D expenses were incurred for the three months ended March 31, 2022.~~Contents

Other Income, Net

Other income, net increased by ~~$54,000~~$2.3 million to ~~$55,000~~$2.3 million for the three months ended March 31, ~~2022~~2023 from ~~$1,000~~$55 thousand for the three months ended March 31, ~~2021.~~2022. The increase was primarily attributable to an increase in interest and investment income due to higher ~~interest~~ yields ~~and an increase in~~on our interest-earning assets.

~~Table of Contents~~

Liquidity and Capital Resources

From our inception through March 31, ~~2022,~~2023, we raised an aggregate of ~~$426.0~~$579.3 million through equity financings including private placements of preferred stock before we became a public company, ~~and~~ our private placement of preferred stock in the February 2021 Financing and registered offerings of our common stock, ~~and~~including our at-the-market offering programs. As of March 31, ~~2022,~~2023, we had $213.3 million in cash, cash equivalents and short-term investments. Based on our current operating plan, we expect that our cash, cash equivalents and short-term investments as of ~~$112.8 million. We expect that our existing cash , cash equivalents and short-term investments~~March 31, 2023 are sufficient to ~~support~~fund our operating expenses and capital ~~expenditures~~expenditure requirements through ~~2023. We have based this estimate on assumptions that~~the first half of 2025. Advancing the development of STAR-0215 and other product candidates will require a significant amount of capital. Our existing cash and cash equivalents will not be sufficient to fund any of our product candidates through regulatory approval. Furthermore, our operating plan may ~~prove~~change as a result of many factors currently unknown to ~~be wrong,~~us, and we ~~could exhaust~~may need to seek additional financing to fund our ~~available capital resources~~long-term operations sooner than ~~we anticipate.~~planned.

We will need to obtain substantial additional funding to complete the development and commercialization of STAR-0215 or any future product candidates, ~~and~~ support our continuing operations, future clinical trials and the expansion of our pipeline. In addition, STAR-0215 or any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of product candidates that we do not expect to be commercially available for years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of our stockholders. ~~Market~~General economic conditions, both inside and outside the United States, including heightened inflation, capital market instability and volatility, ~~inflation,~~ interest rate and currency rate fluctuations and ~~concerns related to~~economic slowdown or recession as well as the COVID-19 pandemic and geopolitical events, including civil or political unrest (such as the Ukraine-Russian war), may have a significant impact on the availability of funding sources and the terms on which any funding may be available. In addition, market instability and volatility, high levels of inflation and interest rate fluctuations may increase our cost of financing or restrict our access to potential sources of future liquidity. If we fail to raise capital as, and when, needed, we may be unable to continue our operations at planned levels and be forced to modify our business strategies and reduce or terminate our operations. Although we will continue to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations when needed or at all.

~~February 2021~~December 2022 Financing

On ~~January 28, 2021,~~December 19, 2022, we ~~entered into the Purchase Agreement and sold~~closed an ~~aggregate~~underwritten public offering of ~~35,573~~10,445,050 shares of ~~Series X Preferred Stock on the February 1, 2021 closing date~~our common stock for gross proceeds of approximately ~~$110.0~~$115 million, and net proceeds of ~~$104.3~~$107.6 million.

At-the-Market ~~Offering~~Offerings

We had entered into various sales agreements with Cowen and Company LLC , or Cowen, pursuant to which we could issue and sell shares of common stock, under at-the-market offering programs. On May 20, 2021, we terminated our sales agreement with Cowen. On June 30, 2021, we entered into an Open Market Sale Agreement^SM with Jefferies LLC, , or Jefferies, pursuant to which we can issue and sell shares of common stock of up to $25.0 million under ~~at-the-market offering programs (collectively, with the Cowen~~an at-the-market offering program, or the Jefferies ATM ~~Programs).~~Program. We pay ~~the~~Jefferies sales agent commissions of 3% of the gross proceeds from any common stock sold through the Jefferies ATM ~~Programs.~~Program. On September 15, 2022, the Jefferies ATM Program was modified to increase the amount of our common stock that may be offered thereunder to an aggregate offering price of up to $50.0 million, with $30.5 million of such amount then being available for future issuance. In November 2022, the Jefferies ATM Program was once again modified to increase the amount of our common stock that may be offered thereunder to an aggregate offering price of up to $88.1 million, with $50.0 million of such amount then being available for future issuance. As of March 31, ~~2022, we have not sold any shares~~2023, $50.0 million of common stock ~~pursuant to~~remains available for sale under the Jefferies ~~agreement.~~ATM Program. There was ~~also~~ no activity from the Jefferies ATM ~~Programs~~Program during the three months ended March 31, ~~2021.~~2023 and 2022, respectively.

Table of Contents

Cash Flows

Comparison of the Three Months Ended March 31, ~~2022~~2023 and ~~2021~~2022

The following table provides information regarding our cash flows for the three months ended March 31, ~~2022~~2023 and ~~2021~~2022 (in thousands):



	Three Months Ended March 31,				Three Months Ended March 31,
	2022		2021		2023		2022
Net cash used in operating activities	$	(12,559)	$	(8,716)	$	(13,253)	$	(12,559)
Net cash (used in) provided by investing activities		(27,099)		26,445
Net cash provided by (used in) by investing activities						194,992		(27,099)
Net cash provided by financing activities		—		104,261		37		—
Net (decrease) increase in cash, cash equivalents and restricted cash	$	(39,658)	$	121,990
Net increase (decrease) in cash, cash equivalents and restricted cash					$	181,776	$	(39,658)

Net Cash Used in Operating Activities

Net cash used in operating activities was $13.3 million for the three months ended March 31, 2023 and consisted primarily of a net loss of $11.2 million adjusted for stock-based compensation expense of $1.2 million, an adjustment to our right of use asset of $0.1 million, and a net increase in net assets of $3.4 million, which resulted primarily from a decrease in accrued expenses of $2.5 million, an increase prepaid expenses of $0.9 million and a decrease in the lease liability of $0.1 million, partially offset by an increase in accounts payable of $0.1 million.

Net cash used in operating activities was $12.6 million for the three months ended March 31, 2022 and consisted primarily of a net loss of $15.3 million adjusted for stock-based compensation expense of $1.2 million and expense recognized for warrants of $1.5 million.

22Net Cash Provided by (Used in) Investing Activities

~~Table of Contents~~

Net cash ~~used in operating~~provided by investing activities was ~~$8.7~~$195.0 million for the three months ended March 31, ~~2021~~2023 and consisted primarily of ~~a net loss~~maturities of ~~$170.1 million adjusted for the non-cash portion~~short-term investments of acquired IPR&D of $164.6 million and other non-cash items such as stock-based compensation expense of $0.4 million and a net increase in operating assets of $3.6 million, which resulted primarily from a decrease in accrued expenses of $2.7 million and a decrease in accounts payable of $1.7$290.9 million, partially offset by ~~a decrease in prepaid expenses~~purchases of ~~$0.8~~short-term investments of $95.9 million.

~~Net Cash (Used in) Provided by Investing Activities~~

Net cash used in investing activities was $27.1 million for the three months ended March 31, 2022 and consisted primarily of proceeds from purchases of short-term investments of $81.7 million, partially offset by maturities of short-term investments of $54.6 million. Net cash provided by investing activities was $26.4 million for the three months ended March 31, 2021 and consisted primarily of proceeds from maturities of short-term investments of $20.0 million and cash acquired in the Quellis Acquisition of $6.4 million.

Net Cash Provided by Financing Activities

Net cash provided by financing activities was ~~$104.3 million during~~$37 thousand for the three months ended March 31, ~~2021,~~2023, which was attributable to ~~net~~ proceeds from exercises of ~~$104.3 million from~~stock options. There was no cash provided by financing activities for the ~~February 2021 Financing.~~three months ended March 31, 2022.

Funding Requirements

Our primary uses of capital are for compensation and related expenses, manufacturing costs for preclinical and clinical materials, third party preclinical and clinical research and development services, clinical costs, legal and other regulatory expenses, and general overhead.

As of March 31, ~~2022,~~2023, we had an accumulated deficit of ~~$471.1~~$518.8 million. We have been primarily involved with research and development activities and have incurred operating losses and negative cash flows from operations since our inception.

As of March 31, ~~2022,~~2023, we had available cash, cash equivalents and short-term investments of ~~$112.8~~$213.3 million. WeBased on our current operating plan, we expect that our ~~existing~~ cash, , cash equivalents and short-term investments as of March 31, 2023 are sufficient to ~~support~~fund our operating expenses and capital expenditures requirements through ~~2023.~~the first half of 2025.

Table of Contents

Our estimate as to how long we expect our cash, cash equivalents and short-term investments to be able to fund our operations is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. Our future funding requirements will depend on many factors, including:

●

the progress, timing, costs and results of clinical trials of, and research and preclinical development efforts for, STAR-0215 and any future product candidates, including potential future clinical trials;

●

our ability to enter into and the terms and timing of any ~~additional~~ collaborations, licensing or other arrangements that we may establish;

●

the number and characteristics of future product candidates that we pursue and their development requirements;

●

the outcome, timing and costs of seeking regulatory approvals;

●

the costs of commercialization activities for any of our product candidates that receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing product sales, marketing, market access, distribution, supply chain and manufacturing capabilities, and scaling up the manufacturing of drug substance and drug product to clinical and commercial scale and developing a drug device combination, if applicable, securing all raw materials necessary to conduct such scale-up and successfully completing all other activities related thereto;

●

if we obtain marketing approval of any of our product candidates, ~~revenues,~~revenue, if any, received from commercial sales of our product candidates;

●

if we obtain marketing approval of any of our product candidates, our ability to successfully compete against other approved products that are approved or used as treatments for the indications for which our products are approved, including with respect to STAR-0215 in HAE;

●

our headcount growth and associated costs;

~~Table of Contents~~

●

the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;

●

the impact of the COVID-19 pandemic on our operations, business and prospects; and

●

the costs of operating as a public company.

Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, STAR-0215 or any future product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of medicines that we do not expect to be commercially available for years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all.

Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights. Debt financing, if available, would result in periodic payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends, that could adversely impact our ability to conduct our business.

If we raise funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds ~~through equity or debt financings~~ when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

~~Material Cash Requirements from Known Contractual Obligations~~

~~The following table summarizes our significant contractual obligations as of payment due date by period at March 31, 2022:~~

Payments due by period

Less than 1

More than 3
(In thousands)

Total

Year

1 - 3 Years

Years
Operating lease obligations (1)

1,625

731

894

—
Payments under vendor agreements (2)

766

766

—

—
Total contractual cash obligations

$
2,391

$
1,497

$
894

$
—

~~(1)Represents future minimum lease payments under our non-cancelable operating leases. The minimum lease payments above do not include any related common area maintenance charges or real estate taxes.~~

~~(2)Represents future milestone payments under vendor agreements if certain clinical milestones related to the planned Phase 1a clinical trials of the STAR-0215 program are met.~~

As of March 31, 2022, material contractual obligations included our facility leases pursuant to which we will make payments of $1.6 million. These payments include those pursuant to our current facility lease until its expiration in June 2022 as well as a new sublease we entered into in January 2022, as described in Note 7, “~~Commitments~~”, commencing in May 2022 through its expiration in June 2024. As of March 31, 2022, also have material contractual obligations to certain vendors to which we will make payments of $0.8 million if certain clinical milestones related to the planned Phase 1a clinical trials of STAR-0215 are met.

We enter into agreements in the normal course of business with vendors for preclinical research studies and other services and products for operating purposes. We have not included these payments in the table of contractual obligations above since the contracts are cancelable at any time by us, generally upon 60 days’ prior written notice, and therefore we believe that our non-cancelable obligations under these agreements are not material.

2423

Table of Contents

Item 4. Controls and Procedures

Management’s Evaluation of our Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, or the Exchange Act) that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is (1) recorded, processed, summarized, and reported within the time periods specified in the U.S. Securities and Exchange Commission’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.

Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of March 31, ~~2022,~~2023, our disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

During the three months ended March 31, ~~2022,~~2023, there were no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15(d)-15(f) promulgated under the Exchange Act, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

2524

Table of Contents

PART II – OTHER INFORMATION

Item 1A. Risk Factors

Careful consideration should be given to the factors discussed in Part I, Item 1A, Risk Factors, in our ~~2021~~ Annual Report on Form 10-K for the fiscal year ended December 31, 2022, which could materially affect our business, financial condition or future results, in addition to the information set forth in this Quarterly Report on Form 10-Q.

Item 6. Exhibits

The exhibits filed as part of this Quarterly Report on Form 10-Q are set forth on the Exhibits Index below:


Exhibit Number		Exhibit
10.1		Sublease Agreement, dated as of January 28, 2022, by and between Grant Thornton LLP and the Registrant (incorporated by reference to Exhibit 10.19 to the Registrant’s Current Report on Form 10-K (File No. 001-37467) filed with the SEC on March 10, 2022)
10.2*		2022 Inducement Stock Incentive Plan, as amended (incorporated by reference to Exhibit 99.1 to the ~~Registrant’s~~Registrant's Current Report on Form 8-K (File No. 001-37467) filed with the SEC on February ~~22, 2022)~~2, 2023)
10.3*		Form of Nonstatutory Stock Option Agreement under the 2022 Inducement Stock Incentive Plan (incorporated by reference to Exhibit 99.2 to the Registrant’s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on February 22, 2022)
10.4*		~~Amended and Restated 2015 Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Registrant’s Current Report on Form 8-K (File No. 001-37467) filed with the SEC on December 15, 2021)~~
10.5*		~~Form of Incentive Stock Option Agreement under 2015 Stock Incentive Plan~~
10.6*		~~Form of Nonstatutory Stock Option Agreement under 2015 Stock Incentive Plan~~
10.7*		~~2015 Employee Stock Purchase Plan~~
10.8*		~~Amended and Restated Executive Severance Benefits Plan effective October 7, 2020~~
~~31.1~~31.1*		Certification of principal executive officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
~~31.2~~31.2*		Certification of principal financial officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
~~32.1~~32.1**		Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of The Sarbanes-Oxley Act of 2002, by the Registrant’s principal executive officer and principal financial officer
101.INS		Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Presentation Linkbase Document
104		Cover Page Data File (the cover page XBRL tags are embedded within the iXBRL document).

* ~~Management contract or compensatory plan arrangement.~~Filed herewith.

** Furnished herewith.

2625

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


	Astria Therapeutics, Inc.

Date: May ~~12, 2022~~11, 2023	By:	/s/ NOAH C. CLAUSER
		Noah C. Clauser
		Chief Financial Officer (Principal Financial Officer)

2726


	Series X	Common Stock
	Preferred	Issuable Upon
	Stock at	Conversion at
	Transaction	Transaction
	Date	Date
Shares issued in merger	50,504	8,417,502
Shares issued in February 2021 Financing	35,573	5,928,952
Warrant assumed in merger	2,805	467,500
Total	88,882	14,813,954


Acquired IPR&D	$	164,612
Cash and cash equivalents		8,307
Prepaid expenses and other assets		136
Accounts payable		(1,974)
Accrued liabilities		(400)
Net acquired tangible assets	$	170,681


	As of March 31, 2022
	Quoted
	Prices		Significant		Significant
	in Active		Observable		Unobservable
	Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash equivalents:
Money market funds	$	8,145	$	—	$	—	$	8,145
Corporate debt securities		—		4,396		—		4,396
Commercial paper		—		3,996		—		3,996
Reverse repurchase agreements		—		3,000		—		3,000
Short term investments
Corporate debt securities		—		17,121		—		17,121
Commercial paper		—		5,980		—		5,980
Yankee securities		—		4,029		—		4,029
Treasury bills		1,999		—		—		1,999
Reverse repurchase agreements		—		37,000		—		37,000
Total	$	10,144	$	75,522	$	—	$	85,666


	As of December 31, 2021
	Quoted
	Prices		Significant		Significant
	in Active		Observable		Unobservable
	Markets		Inputs		Inputs
	(Level 1)		(Level 2)		(Level 3)		Total
Assets:
Cash equivalents:
Money market funds	$	1,853	$	—	$	—	$	1,853
Short-term investments:
Reverse repurchase agreements		—		39,000		—		39,000
Total	$	1,853	$	39,000	$	—	$	40,853


Period Ending December 31,	Amount
2022	$	188
Total lease payments	$	188
Less: imputed interest		(4)
Total operating lease liabilities	$	184


	Payments due by period
			Less than 1				More than 3
(In thousands)	Total		Year		1 - 3 Years		Years
Operating lease obligations (1)		1,625		731		894		—
Payments under vendor agreements (2)		766		766		—		—
Total contractual cash obligations	$	2,391	$	1,497	$	894	$	—